Back to results
US 9,701,636 B2Granted
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
AssigneeAkebia Therapeutics, Inc.
InventorsJames Densmore Copp, Ann W. Newman, Anne Luong
Life of this patent
Estimating the term…
Abstract
Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
Claims11
A pharmaceutical composition comprising a crystalline Compound (I):
- wherein the crystalline Compound (I) has an X-ray powder diffraction pattern comprising peaks at approximately 15.0, 18.1, 20.3, 22.9, 24.0, 24.2, 26.3, 26.8, 35.2, and 37.4° 2θ and a melting point at 175.8° C.±5%;
- and
- wherein the pharmaceutical composition comprises less than 10% by weight of any other crystalline Compound (I).
A pharmaceutical composition comprising a crystalline Compound (I):
- wherein the crystalline Compound (I) has an X-ray powder diffraction comprising peaks at approximately 15.0, 18.1, 20.3, 22.9, 24.0, 24.2, 26.3, 26.8, 35.2, and 37.4° 2θ and a melting point at 175.8° C.±5%;
- and
- wherein the pharmaceutical composition comprises less than 10% by weight of amorphous Compound (I).
A crystalline Compound (I):
- which has an X-ray powder diffraction pattern comprising peaks at approximately 15.0, 18.1, 20.3, 22.9, 24.0, 24.2, 26.3, 26.8, 35.2, and 37.4° 2θ and a melting point at 175.8° C.±5%;
- and
- wherein the crystalline Compound (I) is at least 99.5% pure as measured by HPLC.
Dependencies are inferred from the claim text.